We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
From 1 July 2024, the vaccine used in the programme will change to ADACEL® (Tdap).
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
The MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion)
Substances that are classed as persistent organic pollutants (POPs) and when you're allowed to use them.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices, and information about the publication of two recent Device Safety Information pages. The article also includes information on a recent National Patient Safety Alert...
Requesting comments on draft Stockholm Convention proposals for 3 chemical substances.
Urgent safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Information about the risks of taking valproate medicines during pregnancy.
How a marketing authorisation holder should report a defect with a veterinary medicine.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
Product Safety Report for PTS Packers and Providers Pvt Surfaz-SN Triple Action Cream presenting a serious chemical risk.
Check for listed disinfectants for aquaculture; or apply to have your product listed.
Product Safety Report for Uniparco Pure White Cosmetics Gold Glowing presenting a serious chemical risk.
Product Safety Report for Fabrique Par Rodis White Secret Unifying Complexion Serum presenting a serious chemical risk.
Guidance for the veterinary pharmaceutical industry on the production of mock-ups for assessment.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).